Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents: myopathy-myosin-critical illness

1997 ◽  
Vol 7 (6-7) ◽  
pp. 446-447
Author(s):  
N. Deconinck ◽  
V. Van Parijs ◽  
P.F. Laterre ◽  
M. Reynaert ◽  
R. Vormezeele ◽  
...  
2013 ◽  
Vol 45 (12) ◽  
pp. 477-486 ◽  
Author(s):  
Varuna C. Banduseela ◽  
Yi-Wen Chen ◽  
Hanna Göransson Kultima ◽  
Holly S. Norman ◽  
Sudhakar Aare ◽  
...  

Critical illness myopathy (CIM) is characterized by a preferential loss of the motor protein myosin, muscle wasting, and impaired muscle function in critically ill intensive care unit (ICU) patients. CIM is associated with severe morbidity and mortality and has a significant negative socioeconomic effect. Neuromuscular blocking agents, corticosteroids, sepsis, mechanical ventilation, and immobilization have been implicated as important risk factors, but the causal relationship between CIM and the risk factors has not been established. A porcine ICU model has been used to determine the immediate molecular and cellular cascades that may contribute to the pathogenesis prior to myosin loss and extensive muscle wasting. Expression profiles have been compared between pigs exposed to the ICU interventions, i.e., mechanically ventilated, sedated, and immobilized for 5 days, with pigs exposed to critical illness interventions, i.e., neuromuscular blocking agents, corticosteroids, and induced sepsis in addition to the ICU interventions for 5 days. Impaired autophagy as well as impaired chaperone expression and protein synthesis were observed in the skeletal muscle in response to critical illness interventions. A novel finding in this study is impaired core autophagy machinery in response to critical illness interventions, which when in concert with downregulated chaperone expression and protein synthesis may collectively affect the proteostasis in skeletal muscle and may exacerbate the disease progression in CIM.


2016 ◽  
Vol 44 (11) ◽  
pp. 2070-2078 ◽  
Author(s):  
David R. Price ◽  
Mark E. Mikkelsen ◽  
Craig A. Umscheid ◽  
Ehrin J. Armstrong

2021 ◽  
pp. 0310057X2096857
Author(s):  
Brian L Erstad ◽  
Jeffrey F Barletta

There is no consensus on which weight clinicians should use for weight-based dosing of neuromuscular blocking agents (NMBAs), as exemplified by differing or absent recommendations in clinical practice guidelines. The purpose of this paper is to review studies that evaluated various size descriptors for weight-based dosing of succinylcholine and non-depolarising NMBAs, and to provide recommendations for the descriptors of choice for the weight-based dosing of these agents in patients with obesity. All of the studies conducted to date involving depolarising and non-depolarising NMBAs in patients with obesity have assessed single doses or short-term infusions conducted in perioperative settings. Recognising that any final dosing regimen must take into account patient-specific considerations, the available evidence suggests that actual body weight is the size descriptor of choice for weight-based dosing of succinylcholine and that ideal body weight, or an adjusted (or lean) body weight, is the size descriptor of choice for weight-based dosing of non-depolarising NMBAs.


2009 ◽  
Vol 24 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Cynthia A. Lien ◽  
Peter Savard ◽  
Matthew Belmont ◽  
Hiorshi Sunaga ◽  
John J. Savarese

Sign in / Sign up

Export Citation Format

Share Document